Polycomb group expression signatures in the malignant progression of gliomas.
Polycomb group expression signatures in the malignant progression of gliomas.
复制标题
胶质瘤恶性进展中的多梳组表达特征
DOI：
10.3892/ol.2017.5753
复制
发表时间：
2017-04
期刊：
影响因子：
2.9
通讯作者：
You Y
中科院分区：
文献类型：
--
作者：
Hu Q;Wu W;Zeng A;Yu T;Shen F;Nie E;Wang Y;Liu N;Zhang J;You Y
Polycomb group （PcG）蛋白形成至少两个关键复合物，即Polycomb抑制复合物1和Polycomb抑制复合物2。这些复合物与各种癌症的发展有关。关于PcG成员在胶质瘤中的异常表达尚未有系统的研究。利用中国胶质瘤基因组图谱数据集，分析正常脑组织和胶质瘤样本之间PcG的表达模式，并利用BRB Cox回归和风险评分模型开发基于PcG的分类器。这些结果在独立的GSE16011集中得到验证。共鉴定出6种PcGs [chromobox protein homolog (CBX) 6、CBX7、PHD finger protein 1、zeste enhancer of zeste homolog 2 （EZH2）、DNA (cytocine -5-)-methyltransferase 3β (DNMT3B)和polyhomotic样蛋白2]与胶质瘤分级相关。生存分析发现5 - pcg基因标记1个保护基因（zeste同源物增强子1）和4个危险基因（EZH2、PHD指蛋白19、DNMT3A和DNMT3B），可以识别胶质瘤预后不良的高危患者。多因素Cox分析表明，5 - pcg特征是一个独立的预后生物标志物。这些发现表明，一种新的预后分类器，即5 - pcg特征，可以作为胶质瘤患者的独立预后标志物。
Polycomb group (PcG) proteins form at least two key complexes, namely polycomb repressive complex 1 and polycomb repressive complex 2. These complexes are involved in the progression of various cancers. Systematic research has not been conducted on the aberrant expression of PcG members in gliomas. Using the Chinese Glioma Genome Atlas data set, PcG expression patterns between normal brain tissues and glioma samples were analyzed, and a PcG-based classifier was then developed using BRB Cox regression and risk-score model. These results were validated in an independent GSE16011 set. A total of six PcGs [chromobox protein homolog (CBX) 6, CBX7, PHD finger protein 1, enhancer of zeste homolog 2 (EZH2), DNA (cytosine-5-)-methyltransferase 3β (DNMT3B) and polyhomeotic-like protein 2] were identified to be associated with glioma grade. Survival analysis then revealed a five-PcG gene signature one protective gene (enhancer of zeste homolog 1) and four risky genes (EZH2, PHD finger protein 19, DNMT3A and DNMT3B), which may identify patients with high risk of poor prognosis of glioma. Multivariate Cox analysis indicated that the five-PcG signature was an independent prognostic biomarker. These findings indicated that a novel prognostic classifier, five-PcG signature, served as an independent prognostic marker for patients with glioma.